BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

BioAge Labs, Inc.NASDAQ: BIOA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 97.7%

Gross margin was 97.7% in Q1 FY2026, down 2.3 pp from a year earlier. On a trailing-twelve-month basis it was 99.4%, down 0.6 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
97.7%-2.3 pp QoQ
Last fiscal yearDec 2025
100.0%— YoY
LTMMar 2026
99.4%-0.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.3 pp——
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
—

Gross Margin vs competitors

How BIOA compares with its peers on the latest reported figures

  • BIOA's LTM Mar 2026 gross margin of 99.4% is the highest of the 7 companies compared; the peer median is 28.0%.
  • Its year-over-year change of -0.6 pp is the 4th highest of 6, against a peer median of +2.0 pp.
BIOA Competitors Peer median
Gross Margin for BIOA and competitors
Company Period LTM level YoY 3-year change
BIOABioAge Labs, Inc.LTM Mar 202699.4% -0.6 pp—
ACBAurora Cannabis Inc.LTM Mar 202656.6% +2.0 pp-1.4 pp
TKNOAlpha Teknova, Inc.LTM Mar 202633.3% +12.3 pp-9.0 pp
LFCRLifecore Biomedical, Inc.LTM Mar 202631.2% —-3.8 pp
CGCCanopy Growth CorporationLTM Mar 202624.9% -4.7 pp+39.2 pp
EDITEditas Medicine, Inc.LTM Mar 20265.8% +124.1 pp+32.1 pp
HUMAHumacyte, Inc.LTM Mar 2026-748.5% -729.4 pp-309.0 pp
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
CABACabaletta Bio, Inc.FY2025— ——
Peer median (excluding BIOA) 28.0%+2.0 pp-2.6 pp

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.